← Leaderboards
Maura L Gillison
Johns Hopkins University
$5,649,784
Attributed
$5,886,029
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,886,029 · 13
By mechanism
R01$4,500,426 · 3
M01$898,872 · 8
R21$486,731 · 1
P50$0 · 1
Top collaborators
- Richard A Padgett1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Gypsyamber D'souza$25,879,984
- Joseph A Califano$16,242,638
- Richard Bruce Roden$11,133,737
- Karen L. Beemon$8,952,439
- Keerti V Shah$1,723,017
Others in their field
Top investigators on “Head And Neck Squamous Cell Carcinoma”
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$17,047,548
- Cun-Yu Wang · University Of California Los Angeles$14,843,475
- Lorraine J Gudas · Sloan-Kettering Institute For Cancer Res$11,559,006
- Qingyi Wei · University Of Texas Md Anderson Can Ctr$11,102,171
- Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh$10,353,289
- Xiao-Jing Wang · University Of California At Davis$9,895,933
Research focus
Head And Neck Squamous Cell CarcinomaFuturePapillomavirus, HumanMalignant NeoplasmsHuman Papillomavirus 16ResourcesPlayUnited States National Institutes Of HealthOralHead And Neck CancerFundingInstitutionClinical ResearchDesignRisk FactorsAffectPrevalenceHpv-High RiskHuman Papilloma Virus InfectionOropharyngealMalignant Neoplasm Of OropharynxIncidenceMolecularDetection
Grant awards (21)
Functional consequences of mutations in spliceosomal small nuclear RNAs$472,491
R01 · FY2022 · GM
PREVALENCE AND DETERMINANTS OF ORAL HPV INFECTION IN THE US POPULATION$727,791
R01 · FY2013 · DE · contact PI
PREVALENCE AND DETERMINANTS OF ORAL HPV INFECTION IN THE US POPULATION$754,633
R01 · FY2012 · DE · contact PI
Oral HPV Infection in HIV-Infected Men and Women$338,750
R01 · FY2008 · DE · contact PI
Oral HPV Infection in HIV-Infected Men and Women$279,733
R01 · FY2008 · DE · contact PI
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer$202,385
R21 · FY2008 · CA · contact PI
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer$18,709
R21 · FY2008 · CA · contact PI
Oral HPV Infection in HIV-Infected Men and Women$626,352
R01 · FY2007 · DE · contact PI
A Therapeutic Vaccine for HPV 16-Positive Head and Neck Cancer$265,637
R21 · FY2007 · CA · contact PI
HUMAN ORAL PAPILLOMAVIRUS ETIOLOGY (HOPE) STUDY$136,957
M01 · FY2007 · RR · contact PI
HOPE PILOT 2$14,433
M01 · FY2007 · RR · contact PI
HEAD AND NECK SQUAMOUS CELL CARCINOMA$1,088
M01 · FY2007 · RR · contact PI
OSI-774 IN PATIENTS WITH ORAL CAVITY OR OROPHARYNGEAL CANCER$450
M01 · FY2007 · RR · contact PI
HOPE PILOT 2$744,035
M01 · FY2006 · RR · contact PI
Oral HPV Infection in HIV-Infected Men and Women$644,443
R01 · FY2006 · DE · contact PI
HEAD AND NECK SQUAMOUS CELL CARCINOMA$548
M01 · FY2006 · RR · contact PI
OSI-774 IN PATIENTS WITH ORAL CAVITY OR OROPHARYNGEAL CANCER$548
M01 · FY2006 · RR · contact PI
Oral HPV Infection in HIV-Infected Men and Women$656,233
R01 · FY2005 · DE
OSI-774 IN PATIENTS WITH ORAL CAVITY OR OROPHARYNGEAL CANCER$499
M01 · FY2005 · RR
OSI-774 in patients with oral cavity or oropharyngeal cancer$314
M01 · FY2004 · RR
HPV Vaccine Therapy /Correlates in Head/Neck carcinoma$0
P50 · FY2002 · CA